Cargando…
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
Autor principal: | Seo, Ji A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834841/ https://www.ncbi.nlm.nih.gov/pubmed/31694080 http://dx.doi.org/10.4093/dmj.2019.0173 |
Ejemplares similares
-
Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
por: Sasaki, Takashi
Publicado: (2018) -
Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function
por: Lee, Hong Kyu
Publicado: (2019) -
Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?
por: McDowell, Kirsty, et al.
Publicado: (2021) -
Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020) -
Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)